Olema Oncology's Upcoming Investor Engagements
Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA) is a forward-thinking clinical-stage biopharmaceutical company located in San Francisco. The organization's focus is on developing targeted therapies aimed at advancing treatment options for breast cancer and other conditions. Recently, Olema announced its participation in several key investor conferences, which presents an excellent opportunity to gain insights into the company's ongoing innovations and pipeline developments.
Investor Conferences Participation
The company is gearing up for the following significant events:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date and Time: November 10 at 10:30 a.m. ET.
Format: Fireside Chat.
UBS Global Healthcare Conference 2025
Date and Time: November 12 at 8:00 a.m. ET.
Format: Presentation.
2025 Jefferies London Healthcare Conference
Date and Time: November 19 at 9:00 a.m. GMT / 4:00 a.m. ET.
Format: Fireside Chat.
During these conferences, interested parties can look forward to live webcasts and recordings, which will be accessible shortly thereafter, as authorized by the respective hosts. This is an excellent opportunity for investors and the public to understand the innovations and developments applied by Olema Oncology.
About Olema Oncology
Olema is passionately committed to transforming the treatment landscape for patients contending with breast cancer and related hormone-driven malignancies. Leveraging an in-depth understanding of endocrine-driven cancers and mechanisms of acquired drug resistance, the company is developing groundbreaking therapies. The focus of Olema's current efforts includes its lead product candidate, palazestrant (OP-1250), a unique orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). This groundbreaking drug is currently involved in two Phase 3 clinical trials.
In addition, Olema is advancing OP-3136, a promising lysine acetyltransferase 6 (KAT6) inhibitor that is currently evaluated in a Phase 1 clinical study. These advancements exemplify Olema's dedication to revolutionizing patient outcomes through innovative therapeutic avenues.
Olema has established itself as a leader in addressing the unmet needs of patients with breast cancer by advancing a robust pipeline of therapies rooted in cutting-edge science.
Company Communication and Contact Information
To learn more about Olema's ongoing projects and developments, stakeholders can visit the company's investor relations website. For direct inquiries, interested parties can reach out to the communication department. Here is the contact information:
Media and Investor Relations
Contact: Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
Email: media@olema.com
Frequently Asked Questions
What is Olema Oncology's main focus?
Olema Oncology is focused on developing targeted therapies for breast cancer and related conditions.
When will Olema participate in investor conferences?
Olema will participate in three upcoming conferences in November, including the Guggenheim, UBS, and Jefferies London Healthcare Conferences.
What is palazestrant (OP-1250)?
Palazestrant is Olema's lead product candidate, designed as a complete estrogen receptor antagonist and selective estrogen receptor degrader.
How can I access Olema's conference presentations?
Live webcasts and recordings from the conferences will be available on Olema's investor relations website.
Who can I contact for more information about Olema?
For inquiries, individuals can contact Courtney O’Konek via email at media@olema.com.
